Released March 14, 2012 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Industrial Info Resources is pleased to announce the release of the 2012 Pharmaceutical & Biotech Industry Outlook. With the entire industry in a state of transition, the importance of having a tool that provides understanding and knowledge has never been more essential. Tap into the pulse of the North American Pharmaceutical & Biotech Industry, using a clear, concise format that demystifies this lucrative and constantly evolving industry.
The 2012 Pharmaceutical & Biotech Industry Outlook provides insight into a market that is currently anticipating facility construction starts of more than $15 billion before the year is over. Each year, Industrial Info Resources provides an overall spending forecast, with the numbers representing total expenditures for capital and maintenance as they relate to the North American Pharmaceutical & Biotech Industry. The forecast is derived by applying a confidence factor based on historical spending trends to the baseline project activity that Industrial Info is currently tracking. We then use actual projects identified from our research to analyze the trends as they relate to geography, project type and budget type.
Projects are monitored on a regular basis, providing a "real-time" picture of activity. The dollar amount fluctuates as some are moved out to different years and others are added. As of March 13, 2012, the actual reported count for projects scheduled to begin construction in 2012 in North America was 703, representing a total investment value of just over $15 billion. A week before, it was $16 billion, next month it may be $18 billion--that's the nature of our real-time tracking. These projects are measured on the scheduled kickoff date and are valued at $1 million and greater.
When using the 2012 Pharmaceutical & Biotech Industry Outlook, there is no need for the endless searching that often nets too much information that overwhelms rather than informs. Industrial Info has done the homework for you and packaged useful, timely and essential information and statistics into one easy-to-use format. Features include upcoming trends, vital plant and project statistics, as well as a capital and maintenance spending analysis derived from our information databases.
Setting the outlook apart from any aspiring competitors is that, in addition to having access to its clearly written editorial content, subscribers receive exclusive quarterly updates on 2012 plant and project spending statistics through our online version. It is important to understand that unlike other outlooks or forecasts that offer statistical information, our data is based on phone-verified project and plant information, conducted by our in-house staff of research specialists.
Be sure to check out the popular Annual Pharmaceutical/Biotech Industry Performance Lists. Filled with the latest data regarding the top companies' financials, best-selling products and more, this year's compilation is the largest yet. Lists included in the 2012 Pharmaceutical & Biotech Industry Outlook are as follows:
Company/Sector Data
If you will be in New York May 1-3, 2012, for the Interphex Pharmaceutical Convention, make sure to stop by Booth 2464 at the Jacob K. Javits Convention Center. We would be delighted to meet with you and give you a hands-on sample of our entire product line.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, and eight offices outside of North America, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
The 2012 Pharmaceutical & Biotech Industry Outlook provides insight into a market that is currently anticipating facility construction starts of more than $15 billion before the year is over. Each year, Industrial Info Resources provides an overall spending forecast, with the numbers representing total expenditures for capital and maintenance as they relate to the North American Pharmaceutical & Biotech Industry. The forecast is derived by applying a confidence factor based on historical spending trends to the baseline project activity that Industrial Info is currently tracking. We then use actual projects identified from our research to analyze the trends as they relate to geography, project type and budget type.
Projects are monitored on a regular basis, providing a "real-time" picture of activity. The dollar amount fluctuates as some are moved out to different years and others are added. As of March 13, 2012, the actual reported count for projects scheduled to begin construction in 2012 in North America was 703, representing a total investment value of just over $15 billion. A week before, it was $16 billion, next month it may be $18 billion--that's the nature of our real-time tracking. These projects are measured on the scheduled kickoff date and are valued at $1 million and greater.
When using the 2012 Pharmaceutical & Biotech Industry Outlook, there is no need for the endless searching that often nets too much information that overwhelms rather than informs. Industrial Info has done the homework for you and packaged useful, timely and essential information and statistics into one easy-to-use format. Features include upcoming trends, vital plant and project statistics, as well as a capital and maintenance spending analysis derived from our information databases.
Setting the outlook apart from any aspiring competitors is that, in addition to having access to its clearly written editorial content, subscribers receive exclusive quarterly updates on 2012 plant and project spending statistics through our online version. It is important to understand that unlike other outlooks or forecasts that offer statistical information, our data is based on phone-verified project and plant information, conducted by our in-house staff of research specialists.
Be sure to check out the popular Annual Pharmaceutical/Biotech Industry Performance Lists. Filled with the latest data regarding the top companies' financials, best-selling products and more, this year's compilation is the largest yet. Lists included in the 2012 Pharmaceutical & Biotech Industry Outlook are as follows:
Company/Sector Data
- Top 20 Pharmaceutical Company Rankings by 2010 Sales Revenue
- Top 10 Biotech Company Rankings by 2010 Sales Revenue
- Top 10 Biotech Company Rankings by Market Value
- Top 10 Generic Manufacturers by 2010 Sales Revenue
- Top 15 Pharmaceutical Stock 2011 Performance
- Major 2011 Layoff Announcements
- National Health Expenditure Projections through 2020
- PhRMA Member Companies
- Top 20 R&D Spending by Company 2010
- Top Therapeutic Classes Currently in Development
- Top 20 Pharmaceutical Drugs by Sales 2010
- Top 10 Biotech Drugs by Sales 2010
- Top 2011 Industry Mergers & Acquisitions
If you will be in New York May 1-3, 2012, for the Interphex Pharmaceutical Convention, make sure to stop by Booth 2464 at the Jacob K. Javits Convention Center. We would be delighted to meet with you and give you a hands-on sample of our entire product line.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, and eight offices outside of North America, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
